In summary, while CAR T-cell therapies targeting EGFR and EGFRvIII exhibit significant potential and therapeutic specificity in targeting tumor cells, the widespread expression of EGFR continues to pose a risk of unintended toxicity to normal tissues, highlighting the necessity for further research to optimize treatment strategies that balance efficacy and safety. Here, EGFR is linked to neoplasm.